Press

Nucleus’s Community Round Surpasses $500,000 Raised

Apr 28 • 1 min read

In an update today on their Wefunder campaign page, which is slated to close over the weekend, the company announced that it had reached $500,000 in capital raised (with more expected to come in before closing). A few weeks ago, Iter Investments had agreed to fund any capital remaining of the $500,000 as of the…

PSYC Explores the Boundaries of Psychedelics and Society with New Video Series, “PSYC Taboo”

Apr 27 • 5 min read

PSYC Corporation (OTC Pink Market: PSYC), parent company to Spotlight Media Corporation (“SMC” or the “wholly owned subsidiary”), a multimedia leader for all things psychedelics including the emerging medicinal psychedelics market sector, is pleased to announce the premiere of its new independently produced video series “PSYC Taboo” which premieres on Friday, April 28, 2023, via Psychedelic Spotlight…

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial

Apr 27 • 2 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it has formed a Data and Safety Monitoring Board (DSMB) to oversee the company’s first in human clinical trial, for Alcohol Use Disorder (“AUD”)…

Mindbloom Announces Partnership with SHIFT To Offer Affordable At-Home Ketamine Therapy To Its Employees

Apr 26 • 3 min read

-Mindbloom, the world’s largest provider of ketamine therapy, announced today a partnership with SHIFT, a tech-enabled management consulting firm, to provide at-home ketamine therapy as a benefit to its employees. Through this partnership, all SHIFT employees will have access to at-home ketamine therapy through Mindbloom for a fraction of the normal price. “I am incredibly proud…

Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’s Disease With a Proprietary formulation Based On 5-MeO-DMT

Apr 26 • 3 min read

Biomind Labs Inc. (NEO: BMND / OTC: BMNDF / FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has commenced a Phase II clinical trial for its proprietary 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT“)-based BMND08…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435